Efficacy and Safety of the Induction Therapy with Different Doses of Anthracyclines for Patients with Newly Diagnosed Acute Promyelocytic Leukemia.
10.19746/j.cnki.issn.1009-2137.2019.04.007
- Author:
Ya-Xue WU
1
;
Xiao-Hui HU
2
;
Su-Ning CHEN
1
;
Hui-Ying QIU
1
;
Cheng-Cheng FU
1
;
Yue HAN
1
;
Cai-Xia LI
1
;
Xiao MA
1
;
Ai-Ning SUN
1
;
Xiao-Wen TANG
1
;
De-Pei WU
1
Author Information
1. First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis under Ministry of Health, Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou 215006, Jiangsu Provivnce, China.
2. First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis under Ministry of Health, Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou 215006, Jiangsu Provivnce, China,E-mail: hxh27@163.com.
- Publication Type:Journal Article
- MeSH:
Anthracyclines;
Antineoplastic Combined Chemotherapy Protocols;
Humans;
Leukemia, Promyelocytic, Acute;
Remission Induction;
Retrospective Studies;
Treatment Outcome;
Tretinoin
- From:
Journal of Experimental Hematology
2019;27(4):1033-1039
- CountryChina
- Language:Chinese
-
Abstract:
]Objective:To investigate the efficacy and safety of induction regimens containing arsenite, allo-transretinoic acid (ATRA) and anthracyclines of different doses as induction chemotherapy for acute promyelocytic leukemia (APL).
METHODS:The clinical data of 129 consecutive hospitalized newly diagnosed APL patients from January 2011 to December 2017 were collected and retrospectively analyzed. Sixty-six patients received arsenite, ATRA and anthracyclines of low doses (low dose group), while other 63 patients received arsenite, ATRA and anthracyclines of standard doses (standard dose group), the efficacy and safety were compared and analyzed in 2 groups.
RESULTS:There were no statistically significant differences in terms of age, sex, routine blood indexes,LDH level, bone marrow promyelocyte count,prognostic stratification between patients in two groups (P>0.05). During the treatment, WBC count peak and its time point were not significantly different between two groups (P>0.05). Both induction regimens showed good efficacy, the PML-RARα gene conversion rate from positive into negative, the 2-year overall survival rate and disease-free survival rate in the low-dose group were similar to those in the standard dose group(P＞0.05). The recovery time of neutrophils and platelets in the low-dose group was 0 d and 11 d, respectively, which were statistically significantly shorter than those in the standard dose group (3 d,15 d) (both P=0.000). The median value of platelet and erythrocyte transfusion in the low-dose group was 6.9 U and 4.2 U, respectively, which were statistically significantly lower than that in the standard dose group (8.4 U,6.8 U) (P=0.037，0.000). And the inpatient time in the low and the standard dose groups were 30.98 and 30.71 days, respectively (P=0.770).
CONCLUSION:For newly diagnosed patients with APL, the efficacy was similar between induction therapy containing arsenite,ATRA and low dose anthracyclines and the induction therapy containing arsenite, ATRA and standard dose anthracyclines, however, the former appears even safer.
